Emergent said it is separately working on increasing the availability of its overdose reverser on site for businesses.

On Wednesday, Emergent Biosolutions Inc (EBS) stock saw a decline, ending the day at $8.93 which represents a decrease of $-0.29 or -3.15% from the prior close of $9.22. The stock opened at $9.16 and ...

Emergent BioSolutions shows signs of turnaround with restructuring and new contracts in biodefense, but risks remain. Check ...

据贝哲斯咨询发布的2024版铜绿假单胞菌肺炎药物市场分析报告，全球和中国铜绿假单胞菌肺炎药物市场规模在2023年分别达到 亿元（人民币）与 ...

Emergent BioSolutions Inc. (NYSE:EBS) stock is trading higher on Wednesday after the company announced the closing of a $100 ...

Despite revenue challenges, Emergent BioSolutions Inc (EBS) raises guidance and expands NARCAN distribution to meet growing ...

Ongoing support of the ‘White House Challenge to Save Lives from Overdose’ through workplace and public safety measuresOne-year mark of Ready to ...

Emergent BioSolutions Inc.宣布向其执行副总裁、首席财务官兼财务主管Richard S. Lindahl授予特别一次性股权奖励。 董事会薪酬委员会于周三批准授予15,000个限制性股票单位，这些单位将于2025年10月15日归属，前提是Lindahl届时仍在公司任职。

根据最近的SEC文件，生物制药公司Emergent BioSolutions Inc. (NYSE:EBS)已完成未注册的股权证券发行。周一，该公司完成了1,113,338股普通股的分配，每股约8.98美元。这项交易是2024年8月30日签订的信贷协议的一部分，涉及该公司、多个贷款方和OHA Agency LLC作为管理代理。

美国猴痘疫苗概念股Emergent BioSolutions (EBS.US)周三美股盘前一度大涨逾16%，该公司早些时候表示，其已获得约4亿美元的牛痘、天花和猴痘疫苗产品组合订单，将于2024年和2025年交付。截至发稿，该股盘初涨超8%。

US biotech Emergent BioSolutions revealed it has secured approximately $400 million in orders in 2024 and 2025 associated ...

Emergent BioSolutions secures $400M in orders for smallpox and mpox products, receives FDA approval for ACAM2000's expanded ...